"Pneumologisches Studienzentrum MVZ die Lungenaerzte"
- Address
- lock Available on a paid plan
Severe Asthma
The Pneumologisches Studienzentrum MVZ die Lungenaerzte in Berlin is conducting research on Severe Asthma, aiming to test a new therapeutic agent that may lower the frequency of asthma attacks.
- Efficacy of novel biologic therapy
- Reduction of exacerbation frequency
- Safety profile in adult patients
This work reflects the centre’s focus on respiratory health and its commitment to improving outcomes for patients with difficult‑to‑control asthma.
Chronic Obstructive Pulmonary Disease (COPD)
At the same site, investigators are evaluating tozorakimab as an add‑on treatment for COPD patients with a history of moderate to severe exacerbations, particularly former smokers.
- Add‑on therapy to standard care
- Impact on exacerbation rate
- Assessment of safety in symptomatic individuals
These studies support the centre’s dedication to advancing care for chronic respiratory tract diseases across Europe.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 10 by active trials.
No sponsors linked to active trials.
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
No repeated partnerships found.
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 2 310 other sites in Germany
Therapeutic Area Benchmark — Germany
Select a therapeutic area to compare against other sites in Germany.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Germany
Market Share
Country: Germany
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in "Pneumologisches Studienzentrum MVZ die Lungenaerzte"
lock Showing 1 of 2 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| Efficacy and Safety Evaluation of Verekitug (UPB-101) in Adults with Severe Asthma: A Phase 2 Randomized, Double-blind, Placebo-controlled Study | Upstream Bio Inc. | Phase II | Not Recruiting | Jun 2024 | Mar 2026 |
IMP list
lock Showing 1 of 3 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Human IgG1 kappa monoclonal antibody against CRLF2 | 1 | Unknown | 2024-06-19 | 2024-06-19 |
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.